Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

Université du Québec à Montréal

$366,964.00

Probing into low-density lipoprotein receptor-related protein (LPR)-1-independent peptide transcytosis mechanisms

FY 2013-14

Summary
The Laboratory of Molecular Oncology at the Université du Québec à Montréal (UQAM) and under the direction of Professor Borhane Annabi is partnering with AngioChem a Montreal-based company reknown for its unique synthetic strategies applicable to breakthrough pharmacological agents that are optimized to cross the blood-brain barrier (BBB). Such technology will help to better understand molecular and cellular processes involved in central nervous system and brain-related disorders. The current project will investigate the molecular mechanisms involved in intracellular low-density lipoprotein receptor-related protein (LRP)-1 receptor-dependent and independent pathways. Such pathways open up a wide variety of original and sophisticated molecular strategies to explore new and original molecular and cellular processes involved in processes such as angiogenesis and impact of hypoxia (low oxygen levels) on cells and tissues. The current proposed collaborative project is designed to identify and investigate the alternate receptors and/or interacting molecular partners that could be involved in the transport of Angiopeps. This will result in an increased fundamental understanding of the LRP-1 transport mechanisms that will enable novel chemical entities to target critical cellular processes such as those involved in uncontrolled carcinogenic cell proliferation, cell survival, as well as those mechanisms involved in tumour-associated angiogenesis, and in brain-related disorders. The expected benefits will help to accrue to Canadian industry and to UQAM, the targeted areas under investigation in the described joint research and development activities are expected to leverage a breakthrough platform technology enabling physiological transport of bioactive molecules across the BBB. As such, AngioChem currently positions itself as the leader in this field. Academically, the direct benefits to UQAM include valuable training opportunities, increased employment as well as anchoring exciting industrial partnerships to the Montreal region. Scientifically, UQAM's Faculty of Sciences will enormously benefit of increased visibility from such an active partnership.
Program
Collaborative Research and Development Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
445033-2012
Name nom
Annabi, Borhane
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
366964
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
141
Committee name en
University/Industry
Committee name fr
Universités/industrie
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5109
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Intra-cellular targeting
Research subject fr
Cibles intra-cellulaires
Partie
1
Nb partie
3
Application title
Probing into low-density lipoprotein receptor-related protein (LPR)-1-independent peptide transcytosis mechanisms
Keyword
NSERC
Application summary
The Laboratory of Molecular Oncology at the Université du Québec à Montréal (UQAM) and under the direction of Professor Borhane Annabi is partnering with AngioChem a Montreal-based company reknown for its unique synthetic strategies applicable to breakthrough pharmacological agents that are optimized to cross the blood-brain barrier (BBB). Such technology will help to better understand molecular and cellular processes involved in central nervous system and brain-related disorders. The current project will investigate the molecular mechanisms involved in intracellular low-density lipoprotein receptor-related protein (LRP)-1 receptor-dependent and independent pathways. Such pathways open up a wide variety of original and sophisticated molecular strategies to explore new and original molecular and cellular processes involved in processes such as angiogenesis and impact of hypoxia (low oxygen levels) on cells and tissues. The current proposed collaborative project is designed to identify and investigate the alternate receptors and/or interacting molecular partners that could be involved in the transport of Angiopeps. This will result in an increased fundamental understanding of the LRP-1 transport mechanisms that will enable novel chemical entities to target critical cellular processes such as those involved in uncontrolled carcinogenic cell proliferation, cell survival, as well as those mechanisms involved in tumour-associated angiogenesis, and in brain-related disorders. The expected benefits will help to accrue to Canadian industry and to UQAM, the targeted areas under investigation in the described joint research and development activities are expected to leverage a breakthrough platform technology enabling physiological transport of bioactive molecules across the BBB. As such, AngioChem currently positions itself as the leader in this field. Academically, the direct benefits to UQAM include valuable training opportunities, increased employment as well as anchoring exciting industrial partnerships to the Montreal region. Scientifically, UQAM's Faculty of Sciences will enormously benefit of increased visibility from such an active partnership.
Université du Québec à Montréal - $366,964 Grant (201… | Canada Spends